Satti, Suma, MD

Suma Satti, MD
Close

Positions

Sr Physician, Southshore Region
1514 Jefferson Hwy, New Orleans, LA, 70121

For additional information or to make an appointment, click here.

Overview

Dr. Satti earned her medical degree from Kasturba Medical College, Manipal, India. Following graduation, she completed her internship and residency in Internal Medicine and fellowship in Medical Oncology at Ochsner Health System. Dr. Satti has been on staff since October 2008 and is board certified in Internal Medicine.

Selected publications

2022

Molecular profiling of African American patients with pancreatic cancer.. Journal of Clinical Oncology. 40:E16242-E16242.
Web of Science
2022

S1417CD: A Prospective Multicenter Cooperative Group-Led Study of Financial Hardship in Metastatic Colorectal Cancer Patients
Full Text Web of Science
2021

Real-World Data and Racial Outcomes for NSCLC in The Chemo-Immunotherapy Era. Journal of Thoracic Oncology. 16:S1076-S1077.
Web of Science
2020

A phase II trial of pembrolizumab in combination with cisplatin or carboplatin and etoposide in chemotherapy naive patients with metastatic or unresectable high-grade gastroenteropanncreatic or lung neuroendocrine carcinoma. Journal of Clinical Oncology. 38.
Web of Science
2020

Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD.. Journal of Clinical Oncology. 38.
Web of Science
2020

Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered every three weeks in patients with advanced refractory tumors: Efficacy in dose-escalation and expansion cohorts.. Journal of Clinical Oncology. 38.
Web of Science
2019

A Pilot Phase 2 Study of Albumin-Bound Rapamycin Nanoparticles, ABI-009, in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors (NETs) of the Lung or Gastroenteropancreatic System. Pancreas. 48:449-449.
Web of Science
2019

Design and accrual of S1417CD: Development of a prospective financial impact assessment tool in patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 37.
Full Text Web of Science
2019

Phase Ib clinical study of CBP501, cisplatin and nivolumab administered every 3 weeks in patients with advanced refractory tumors. Dose escalation cohort. Cancer Research. 79.
Full Text Web of Science
2017

Outcomes of Patients With Late-Relapse Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Single Institution Experience. The Ochsner Journal. 17:331-334.
PubMed Web of Science
2017

Primary Undifferentiated Pleomorphic Sarcoma of the Penis. The Ochsner Journal. 17:434-437.
PubMed Web of Science
2015

BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Review of Molecular Diagnostics. 15:1201-1210.
Full Text PubMed Web of Science
2015

In vitro synergistic cellular proliferation inhibition in pancreatic cancer cells Su86 and Mia-PaCa-2 with fluvastatin and nab-paclitaxel.. Journal of Clinical Oncology. 33.
Full Text Web of Science
2015

In-vitro synergistic cellular proliferation inhibition in pancreatic cancer cells Su86 and Mia-PaCa-2 with fluvastatin and nab-paclitaxel.. Journal of Clinical Oncology. 33.
Full Text Web of Science
2014

Outcomes of neoadjuvant chemotherapy with FOLFOX/FOLFIRINOX and chemoradiotherapy in borderline resectable pancreatic cancer: Single-institution experience. Journal of Clinical Oncology. 32.
Full Text Web of Science
2013

A single-center experience of modified FOLFOX-6 in locally advanced and metastatic pancreatic adenocarcinomas. Journal of Clinical Oncology. 31.
Full Text Web of Science

Visualizations

Recent publications and grants in ScholarlyWork@Ochsner

Co-author Network

Map of Science

ScholarlyWork@Ochsner

Suma Satti, MD
Close

Overview

Overview

Publications

Selected publications

Visualizations

Research areas